Three of the largest pharmaceutical companies in the world bought psychedelic drug developers within eight months of each other. Lilly paid up to $3.8 billion for a nasal spray of 5-MeO-DMT, the same molecule the Sonoran desert toad has carried for as long as there have been toads. The White House told the FDA to hurry. The smartest money in the world is moving now.

Johnny Tabaie has sat with people through that experience, one on one, under medical supervision, for fifteen years. In his new Medium article he explains what just happened, why it happened now, and what the pharmaceutical version will and will not be able to do: a fixed dose, a few hours in a clinic, and none of the weeks before or after that decide whether the experience becomes a changed life or a strange memory.

Read the full article on Medium: The Future of Psychedelic Therapies: Why Big Pharma Is Betting Billions